MDGL
Price
$278.23
Change
+$4.13 (+1.51%)
Updated
Jun 6 closing price
Capitalization
6.18B
60 days until earnings call
SYBX
Price
$1.21
Change
-$0.01 (-0.82%)
Updated
Jun 6 closing price
Capitalization
14.17M
Interact to see
Advertisement

MDGL vs SYBX

Header iconMDGL vs SYBX Comparison
Open Charts MDGL vs SYBXBanner chart's image
Madrigal Pharmaceuticals
Price$278.23
Change+$4.13 (+1.51%)
Volume$279.61K
Capitalization6.18B
Synlogic
Price$1.21
Change-$0.01 (-0.82%)
Volume$8.91K
Capitalization14.17M
MDGL vs SYBX Comparison Chart
Loading...
MDGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MDGL vs. SYBX commentary
Jun 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MDGL is a Hold and SYBX is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 07, 2025
Stock price -- (MDGL: $278.23 vs. SYBX: $1.21)
Brand notoriety: MDGL and SYBX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MDGL: 77% vs. SYBX: 71%
Market capitalization -- MDGL: $6.18B vs. SYBX: $14.17M
MDGL [@Biotechnology] is valued at $6.18B. SYBX’s [@Biotechnology] market capitalization is $14.17M. The market cap for tickers in the [@Biotechnology] industry ranges from $324.3B to $0. The average market capitalization across the [@Biotechnology] industry is $2.35B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MDGL’s FA Score shows that 0 FA rating(s) are green whileSYBX’s FA Score has 0 green FA rating(s).

  • MDGL’s FA Score: 0 green, 5 red.
  • SYBX’s FA Score: 0 green, 5 red.
According to our system of comparison, MDGL is a better buy in the long-term than SYBX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MDGL’s TA Score shows that 6 TA indicator(s) are bullish.

  • MDGL’s TA Score: 6 bullish, 3 bearish.

Price Growth

MDGL (@Biotechnology) experienced а +1.08% price change this week, while SYBX (@Biotechnology) price change was +5.32% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +9.04%. For the same industry, the average monthly price growth was +14.90%, and the average quarterly price growth was +1.90%.

Reported Earning Dates

MDGL is expected to report earnings on Aug 06, 2025.

SYBX is expected to report earnings on May 08, 2025.

Industries' Descriptions

@Biotechnology (+9.04% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MDGL($6.18B) has a higher market cap than SYBX($14.2M). MDGL YTD gains are higher at: -9.832 vs. SYBX (-13.486). SYBX has higher annual earnings (EBITDA): -23.01M vs. MDGL (-376.15M). MDGL has more cash in the bank: 843M vs. SYBX (18.9M). SYBX has less debt than MDGL: SYBX (0) vs MDGL (120M). MDGL has higher revenues than SYBX: MDGL (317M) vs SYBX (8K).
MDGLSYBXMDGL / SYBX
Capitalization6.18B14.2M43,507%
EBITDA-376.15M-23.01M1,635%
Gain YTD-9.832-13.48673%
P/E RatioN/A5.51-
Revenue317M8K3,962,500%
Total Cash843M18.9M4,460%
Total Debt120M0-
FUNDAMENTALS RATINGS
MDGL vs SYBX: Fundamental Ratings
MDGL
SYBX
OUTLOOK RATING
1..100
559
VALUATION
overvalued / fair valued / undervalued
1..100
63
Fair valued
86
Overvalued
PROFIT vs RISK RATING
1..100
45100
SMR RATING
1..100
9495
PRICE GROWTH RATING
1..100
6261
P/E GROWTH RATING
1..100
10038
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MDGL's Valuation (63) in the Pharmaceuticals Other industry is in the same range as SYBX (86) in the Biotechnology industry. This means that MDGL’s stock grew similarly to SYBX’s over the last 12 months.

MDGL's Profit vs Risk Rating (45) in the Pharmaceuticals Other industry is somewhat better than the same rating for SYBX (100) in the Biotechnology industry. This means that MDGL’s stock grew somewhat faster than SYBX’s over the last 12 months.

MDGL's SMR Rating (94) in the Pharmaceuticals Other industry is in the same range as SYBX (95) in the Biotechnology industry. This means that MDGL’s stock grew similarly to SYBX’s over the last 12 months.

SYBX's Price Growth Rating (61) in the Biotechnology industry is in the same range as MDGL (62) in the Pharmaceuticals Other industry. This means that SYBX’s stock grew similarly to MDGL’s over the last 12 months.

SYBX's P/E Growth Rating (38) in the Biotechnology industry is somewhat better than the same rating for MDGL (100) in the Pharmaceuticals Other industry. This means that SYBX’s stock grew somewhat faster than MDGL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MDGL
RSI
ODDS (%)
Bullish Trend 1 day ago
76%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
76%
Momentum
ODDS (%)
Bullish Trend 1 day ago
79%
MACD
ODDS (%)
Bullish Trend 1 day ago
81%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
75%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
81%
Advances
ODDS (%)
Bullish Trend about 1 month ago
77%
Declines
ODDS (%)
Bearish Trend 2 days ago
81%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
78%
Aroon
ODDS (%)
Bearish Trend 1 day ago
77%
View a ticker or compare two or three
Interact to see
Advertisement
MDGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
FDMT4.350.44
+11.25%
4D Molecular Therapeutics
PWM0.400.02
+6.27%
Prestige Wealth
SHEN13.500.27
+2.04%
Shenandoah Telecommunications Co
BAH103.251.11
+1.09%
Booz Allen Hamilton Holding Corp
ENOV31.790.19
+0.60%
Enovis Corp

SYBX and

Correlation & Price change

A.I.dvisor indicates that over the last year, SYBX has been loosely correlated with NEUP. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if SYBX jumps, then NEUP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SYBX
1D Price
Change %
SYBX100%
-0.72%
NEUP - SYBX
64%
Loosely correlated
-3.92%
BTAI - SYBX
37%
Loosely correlated
+20.26%
SBHMY - SYBX
34%
Loosely correlated
N/A
MDGL - SYBX
31%
Poorly correlated
+1.51%
ATXS - SYBX
30%
Poorly correlated
+14.75%
More